TABLE 1.
SUMMARY OF THE ALTERNATIVE INSULIN DELIVERY PRODUCTS BEING DEVELOPED
| Name | Nature of the product | Company | Stage in the development |
|---|---|---|---|
| Exubera® | Inhaled insulin powder | Pfizer, Sanofi-Aventis and Nektar | FDA and EC approved (January, 2006) |
| AERx® iDMS | Inhaled insulin solution | Aradigm and Novo Nordisk (Novo Nordisk bought all the developing rights) | Phase III in progress |
| Aerodose® | Inhaled insulin solution | Aerogen and Disetronic Medical Systems | Phase II completed |
| HIIP (Device Name Air®) | Inhaled insulin powder | Alkermes and Eli Lilly & Company | Clinical Trial-Phase III (for type 1 and 2) |
| Rapid Mist/Oralin | Mouth spray for buccal delivery (Rapid Mist is device, Oralin is insulin) | Generex Biotechnology | Completed phase II in Canada and Europe. Undisclosed in U.S.A. Oral-lyn™ (identical product) has been approved for commercial marketing and sale by the Ecuadorian Ministry of Public Health for the treatment of both Type-1 and Type-2 diabetes |
| EMISPHERE® oral insulin tablets | Tablet | Emisphere Technologies | Phase II completed |
| NIN-058 (No trade name yet) | Tablet | Nobex Corporation and GlaxoSmithKline | Phase II in progress |
| Patch (No trade name yet) | Basal insulin patch | Altea Development Corporation | Phase I |
AERx® iDMS: AERx® insulin diabetes management system. HIIP: Human insulin inhalation powder. FDA: Food and drug administration. EC: European commission.